The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients
The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients
A randomized, double-blind, placebo-controlled, parallel study to investigate the effect of
 erenumab in calcitonin-gene related peptide and cilostazol experimental models of migraine in
 humans. Followed by a 6-month open-label extension.
Inclusion Criteria:

 -  Patients with migraine with or without aura according to the International
 Classification of Headache Disorders with a frequency of ≥4 migraine days per month

 -  50-100 kg weight

 -  Participants of childbearing potential must use safe contraception (birth control) or
 be sexually abstinent

 Exclusion Criteria:

 -  Any other primary headache disorder according to the International Classification of
 Headache Disorders except for tension-type headache

 -  Any secondary headache disorder according to the International Classification of
 Headache Disorders

 -  Migraine attack during the preceding 48 hours on provocation day

 -  Headache during the preceding 24 hours on provocation day

 -  Treatment with monoclonal antibodies or participation in clinical trials with
 monoclonal antibodies during the preceding year

 -  Daily consumption of any other drug/medication than oral contraception (birth control)

 -  Consumption of any other drug/medication later than four times the plasma half-time of
 the drug on provocation day except for oral contraception

 -  Pregnant or active breastfeeding participants

 -  Any cardiovascular diseases including cerebrovascular disorders

 -  Information in patient history or during physical examination indicating psychiatric
 disorders or substance abuse

 -  Information in patient history or during physical examination that the screening
 physician deems relevant for participation in the study